NASH Clinical Research Network Announced New Trail for Treatment of Liver Cancer

The Nonalcoholic Steatohepatitis (NASH) Clinical Research Network and clinical trials are by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which is one of the National Institutes of Health (NIH). The NASH clinical research network is launching its two primary clinical trials, a liver disease that looks like alcoholic liver disease, but occurs in the patients who only consume little alcohol or no alcohol.

The main cause of Alcoholic liver disease is caused due to the more consumption of alcohol in Western nations. This disease is caused to most of the adults who are over 40 years of age and overweight or have diabetes, insulin resistance (pre-diabetes), or excess concentrations of fatty materials in blood (hyperlipidemia). It can also occur in children, normal-weight, and non-diabetic individuals.

NASH says that there are about 10 percent of newly diagnosed cases are of chronic liver disease. It ranks as one of the leading causes of cirrhosis in the United States, which is followed by hepatitis C and alcoholic liver disease. Here are some of the characteristics of the alcoholic liver disease; abnormal liver enzyme levels, inflammation, liver cell injury, excess amounts of fat stored in the liver, fibrosis in the liver.

The NASH Clinical Research Network is established in September 2002 and consisting of eight clinical centers and a data coordinating center and are conducting research on the pathogenesis, natural history and treatment of NASH. The information collected by adult and pediatric patients, the clinical research network team will maintain all the information and these data are used by researchers in the development of NASH.